Anteris Q2 2026: $260.9M Cash Cushion, but Losses Deepen as PARADIGM Trial Costs Surge; Material Weaknesses Linger
AVR has more than doubled off its 52-week low of $3.175.
Summary
Anteris Technologies reported a widening Q2 loss as PARADIGM trial costs escalate, but holds $260.9M in cash. Material weaknesses in internal controls persist, and the company will soon face accelerated filer requirements.
Updates
· Dow Jones Newswires — Q2 loss was 30 cents per share and sales were $1.01M.
Key Events · Earnings and Guidance · AVR
-
Cash Position Bolstered by January Raise
Cash, equivalents, and restricted cash totaled $260.9 million at June 30, 2026, up from $12.6 million at year-end 2025, primarily due to $320 million in gross proceeds from a public offering and Medtronic private placement in January 2026.
-
Net Loss Widens on Surging R&D
H1 2026 net loss reached $51.7 million, compared to $43.0 million in H1 2025. R&D expenses jumped 24% to $40.8 million, driven by PARADIGM trial activities and manufacturing scale-up.
-
Material Weaknesses Remain Unremediated
Management concluded that disclosure controls and procedures were not effective as of June 30, 2026, due to previously reported material weaknesses in internal control over financial reporting related to lack of designed controls and segregation of duties.
-
Emerging Growth Company Status Ending
Based on public float, Anteris expects to become a large accelerated filer and lose EGC status beginning with its 2026 10-K, requiring SOX 404(b) auditor attestation and accelerated filing deadlines.
Analysis · AVR · Industrial Applications And Services
A net loss of $51.7 million for the first half of 2026 reflects a 24% jump in R&D spending to $40.8 million, as the pivotal PARADIGM trial for its DurAVR heart valve expands. While the company ended June with $260.9 million in cash—thanks to a $320 million capital raise in January—material weaknesses in internal controls remain unremediated, and it expects to lose emerging growth company status by year-end, triggering stricter reporting requirements. A $250 million at-the-market equity program established in May adds potential dilution overhang. The cash runway is strong, but the burn rate is accelerating, and governance concerns linger.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.3% of the 1072 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVR was trading at $9.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $892.6M. The 52-week trading range was $3.18 to $11.06. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.